About Theratechnologies
Theratechnologies is a publicly listed company based in Montreal (Canada) founded in 1993, and was acquired by CB Biotechnology in July 2025. Drugs are developed to reduce abdominal fat from HIV treatments. The company has 105 employees. Theratechnologies has completed 1 acquisition, including Katana Biopharma. Its focus areas include Life Sciences, Metabolic Diseases and Drugs.
Company details
Theratechnologies was founded in 1993 in Montreal, Canada, within the biotechnology sector. Expertise in metabolism and GRF peptides is applied to tackle serious health conditions, with operations centered on product development and commercialization. The initial product, EGRIFT (tesamorelin for injection), received US FDA approval for treating excess abdominal fat linked to lipodystrophy in patients on certain HIV medications.
- Headquarters Montreal, Canada
- Employees 105
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website theratech.com
- Social LinkedIn
- Acquired by CB Biotechnology (Jul 2025)
- Legal Name Theratechnologies Inc.
- Annual Revenue$81.36 M (USD)5.97as on Nov 30, 2024
- Net Profit-$7.87 M (USD)65.02as on Nov 30, 2024
- EBITDA$10.46 M (USD)289.07as on Nov 30, 2024
- Employee Count105
- Investments & Acquisitions
- Acquired byCB Biotechnology
(Jul 2025)
Investors in Theratechnologies
Theratechnologies has secured backing from 1 investor. Prominent investors backing the company include CB Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investor details for Theratechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Theratechnologies
50 people are tracked at Theratechnologies (21 in leadership, 7 in board & advisors, 22 in team); the tracked headcount is 105.
| Name | Role | Group |
|---|---|---|
Philippe Dubuc | SVP and Chief Financial Officer | Leadership |
Jocelyn Lafond | VP, Legal Affairs, and Corporate Secretary | Leadership |
Christian Marsolais | SVP and Chief Medical Officer | Leadership |
Daniel Bock | Senior Director, Business And Corporate Development | Leadership |
André Dupras | VP, Human Resources | Leadership |
Marie-noël Colussi | VP, Finance | Leadership |
Guylaine Roy | Senior Director, Preclinical And Project Management | Leadership |
Peter Kowal | VP, HIV-U.S. Commercial Operations | Leadership |
Jennifer Eliasi | Director Of Thought Leader Liaisons | Leadership |
Paul Lévesque | President and CEO | Leadership |
Harley Cunha | Director Global Regulatory Affairs And Pharmacovigilance | Leadership |
Colleen McGary | Senior Director, Field Medical Affairs | Leadership |
Felix Thiel | Senior Director Finance And Business Operations | Leadership |
Whitney Wells | Head Of Hr, U.s. | Leadership |
Tony di Vincenzo | Director, Sales Operations | Leadership |
Connie Seguin | Director Legal Affairs | Leadership |
Marilyn de Chantal | Director Medical Affairs - Business Development | Leadership |
Shalini Chugh | Director, Marketing Hiv(usa) | Leadership |
Frédéric Leclerc | Director, Global Market Analytics | Leadership |
Leslie Carlyle | Director Of Learning And Development | Leadership |
30 more people are available in the full profile.
Complete people profiles for Theratechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Theratechnologies
Theratechnologies is a publicly listed company on the TSX with ticker symbol TH in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Oct 2015
- Listed onNASDAQ: THTX
- Listed entityTheratechnologies Inc.
- Exchange sectorHealth technology
- Share price4.47 CAD (-4.89% on the day) · 2025-09-29
- Market capitalisation205,530,674.00 CAD
- EPS (diluted, trailing year)-0.27 CAD
- Volume (last session)35,472
- Analyst consensusStrong buy
Financials of Theratechnologies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | 117.1M CAD | -11.3M CAD | 15.1M CAD |
| 2023 | 110.5M CAD | -32.4M CAD | -8.0M CAD |
| 2022 | 103.7M CAD | -61.2M CAD | -36.0M CAD |
| 2021 | 87.5M CAD | -39.8M CAD | -21.0M CAD |
| 2020 | 88.8M CAD | -30.5M CAD | -13.1M CAD |
Detailed financial statements for Theratechnologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Theratechnologies
Theratechnologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Katana Biopharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Targeted oncology technology platform is developed for cancer treatment. | katanabiopharma.com | Canada | 2016 | Feb 2019 | $5.3M |
Complete acquisition details for Theratechnologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Theratechnologies
4 dated milestones of Theratechnologies across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Theratechnologies is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Katana Biopharma.
- Exit Acquired by CB Biotechnology.
Web traffic of Theratechnologies
The website of Theratechnologies (theratech.com) receives about 5.5K visits a month and ranks #5,174,204 among all websites worldwide, #5,911 in Biotechnology and Pharmaceuticals.
- Monthly visits5.5K
▲ 45.6% vs previous month
- Unique visitors1.5K
per month
- Global rank#5,174,204
among all websites
- Category rank#5,911
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.3
- Average visit4 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with Theratechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| chiesi.com | 100% | 112.3K | #413,363 | View details | |
roche.fr | roche.fr | 100% | #533,892 | – | |
serono.fr | serono.fr | 100% | – | ||
dergam.com | dergam.com | 100% | #891,421 | – | |
lilly.fr | lilly.fr | 100% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for Theratechnologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Theratechnologies
Complete news archive for Theratechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Theratechnologies
Theratechnologies was founded in 1993.
Theratechnologies is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Theratechnologies has 105 employees.
Annual revenue of Theratechnologies is $81.36M as on Nov 30, 2024.
Theratechnologies was founded in 1993 in Montreal, Canada, within the biotechnology sector. Expertise in metabolism and GRF peptides is applied to tackle serious health conditions, with operations centered on product development and commercialization. The initial product, EGRIFT (tesamorelin for injection), received US FDA approval for treating excess abdominal fat linked to lipodystrophy in patients on certain HIV medications.
Yes, Theratechnologies is publicly traded on TSX under the ticker symbol TH.
Theratechnologies has made 1 acquisition, including Katana Biopharma.
Theratechnologies has 1 investor. Key investors include CB Biotechnology.
Yes. Theratechnologies was acquired by CB Biotechnology in July 2025.